Background. This study investigated behavioral recovery in rats following implanting increasing doses of CTX0E03 cells into the putamen ipsilateral to the stroke damage. Postmortem histological analysis investigated possible mechanisms of behavioral recovery. Methods. At 4 weeks after middle cerebral artery occlusion (MCAO), rats were treated with 4500, 45 000, or 450 000 CTX0E03 cells or vehicle implanted into the putamen with testing on a battery of tasks preocclusion and postocclusion. Histological examination of brains included assessment of lesion volumes, implant cell survival and differentiation, changes to host brain matrix, angiogenesis, and neurogenesis using immunohistochemical methods. Results. Statistically significant dose-related recovery in sensorimotor function deficits (bilateral asymmetry test [BAT; P < .0002] in the mid-and high-dose groups and rotameter test after amphetamine exposure [P < .05] in the high-dose group) was found in the CTX0E03 cell implanted groups compared to the vehicle group. In-life functional improvements correlated with cell dose, though did not correlate with survival of CTX0E03 cells measured at postmortem. Surviving CTX0E03 cells differentiated into oligodendroglial and endothelial phenotypes. MCAO-induced reduction of neurogenesis in the subventricular zone (SVZ) was partially restored to that observed in sham operated controls. No adverse CTX0E03 cell-related effects were observed during in-life observations or on tissue histology. Conclusions. This study found that the implantation of CTX0E03 human neural stem cells in rats after MCAO stroke promoted significant behavioral recovery depending on cell dose. The authors propose a paracrine trophic mechanism, which is triggered early after CTX0E03 cell implantation, and which in turn targets restoration of neurogenesis in the SVZ of MCAO rats.
S troke in the distribution of the middle cerebral artery accounts for up to 60% of cases, producing a range of sensorimotor and cognitive impairments and related disabilities that can be partially reproduced in animal models after middle cerebral artery occlusion. 1, 2 No pharmacological treatments or biological interventions are available to reverse impairments in patients. A recent approach to the treatment of stroke disability is to promote functional recovery through implantation of neural stem cells directly into the brain. 3, 4 To meet the requirements for clinical application, welldefined and stable cell lines should be manufactured under current Good Manufacturing Practice (cGMP) conditions in quantities that will allow the treatment of significant numbers of patients. For example, hNT neurons, produced from a teratocarcinoma cell line, 5 have been tested in clinical trials in stable stroke patients and were well tolerated, demonstrating the feasibility of neural cell therapy in stroke disability. 6 There is current interest in the use of human neural stem (or neural progenitor) cells or cell lines for regenerative therapy after stroke. We have developed CTX0E03, a clonal human cortical multipotential stem cell line. The line was developed by the genetic modification of first trimester human fetal cortical cells with stable single-copy integration of the cmycER TAM fusion gene, as described in Pollock et al. 3 Function of the fusion protein cmycER TAM in the cells is dependent on the presence of 4-hydroxy-tamoxifen (4-OHT) in the culture media. Expanding CTX0E03 cells in medium supplemented with growth factors and 4-OHT permits large scale, stable expansion in cGMP conditions, retaining their suitability for central nervous system (CNS) implantation. The CTX0E03 cell line has been manufactured into serial cell banks in cGMP facilities and released according to regulatory requirements. Drug substance lots were produced within a narrow range of passage and cell doubling levels, permitting the formulation of a drug product for experimental purposes equivalent to those intended for clinical use. The cell banks and cell lots have been demonstrated to be genetically and phenotypically stable.
In our previous study, 3 CTX0E03 cells at a relatively early passage number were implanted bilaterally 4 weeks after MCAO. The results showed statistically significant improvements in both sensorimotor function and gross motor asymmetry at 6 to 12 weeks postgrafting. 3 In that study, we also reported that the longterm survival of CTX0E03 cells is not a prerequisite for efficacy. This suggests that a cell replacement mechanism is unlikely to be of major importance in this model of stroke. Alternative modes of action may therefore reside with the ability of CTX0E03 cells to induce changes in a host brain.
The objective of the present study was to investigate the effect of implanting increasing doses of CTX0E03 cells directly into the putamen ipsilateral to the stroke damage. In-life safety and behavioral recovery were investigated in the rat MCAO model of stroke in rats. Postmortem histological evaluations were focused on investigations of the mode of action of CTX0E03 and on assessments of safety. Thus, lesion volumes, implant cell survival, differentiation and proliferation, proliferation of host cells in the subventricular zone (SVZ) (neurogenesis), phenotypic and morphological changes, and host brain pathology were investigated using immunohistochemistry and standard histology.
Methods

CTX0E03 Cell Product Preparation
Derivation and culture of the CTX0E03 human neural stem cell line is described in Pollock et al. 3 Vials from a P32-36 drug substance lot, each filled with 5 × 10 6 cells, were taken from cryopreservation and thawed, and cultured in laminin-coated T175 flasks in medium containing 100 nM 4-OHT (Sigma, United Kingdom) and growth factors-basic fibroblast growth factor (Invitrogen, United Kingdom) and epidermal growth factor (Sigma). After a complete medium exchange on day 2 the cells were expanded to 70%, to 90% confluence on day 5, and then dissociated with TrypZean/EDTA (Lonza, United Kingdom) and formulated in Hank's balanced salt solution (HBSS) supplemented with 0.5 mM n-acetyl cysteine (HBSS-NAC) at concentrations to provide target doses of approximately 0, 4500, 45 000, or 450 000 cells/9 μL. Cell viability (>92%) was determined via trypan blue (Sigma) exclusion just prior to delivery to surgical staff. The formulations were coded, blinding surgical staff to the cell dose of the animals.
Animals
A total of 86 male Sprague-Dawley rats (Charles River, United Kingdom) were group housed (12:12, light:dark) and fed ad libitum prior to cell implantation. This study was conducted under a project license approved by the ReNeuron Ethical Review Panel and UK Home Office, and complied with the UK Animals (Scientific Procedures) Act (1986).
Seventy-five rats (320-390 g) underwent right MCAO using the intraluminal filament method. 3, 7, 8 Halothane anesthesia in nitrous oxide/oxygen (60/40) was used for the insertion and removal of filament (3-0 prolene with a 0.28 mm silicone bulb) with body temperature held stable at 37 ± 1°C by rectal probe and heating pad. After the filament was advanced rostrally to the circle of Willis via the common carotid trunk and internal carotid artery, a total of 20 to 22 mm, animals were allowed to recover from the anesthesia and placed in a heated chamber (30°C; Scanbur, Stockholm, Sweden). At 60 minutes, rats were retested for contralateral forelimb flexion, circling behavior, and loss of stepping reflex after whisker stimulation to confirm occlusion of blood flow. Occluded animals that did not demonstrate dysfunction by the end of the occlusion period were removed from the study. At the end of the occlusion period, the animals were reanesthetized, the filament was partially withdrawn with the last 5 mm left in situ in the carotid artery, and the excess filament trimmed away. The wound was sutured shut and the animals were allowed to recuperate in a heated chamber for 2 hours after removal. Eleven animals underwent sham occlusion during which the carotid artery was exposed and a filament left permanently in situ 8 mm in the carotid artery. All animals were given rehydration therapy of 2 mL Duphalyte (Fort Dodge, Southhampton, UK) in 3 mL glucose saline (IVEX) on the first 2 days of recovery from occlusion surgery.
Behavioral dysfunction testing and selection of animals for cell implantation trial. Behavioral dysfunction was assessed using a battery of tests. The timing of behavioral tests, MCAO/ sham procedure, and cell implantation is shown in Table 1 . Behavioral testing performed 1 week prior to MCAO surgery provided a baseline assessment for each animal and animals with rotational bias prior to MCAO (>60% of turns in either direction) were removed from the study.
One day after surgery, the severity of MCAO-induced behavioral and gross motor dysfunction was evaluated using a global neurological scale (Table 1) . 9 Then, 1 to 3 weeks after MCAO, the animals were retested when they had recovered from the acute neurological impairments ( Table 1 ). The rotameter data after amphetamine administration were used a as pass or fail criterion. Only occluded animals with >60% ipsilateral turns toward the lesioned hemisphere were retained for cell implantation (13 excluded) and grouped into cohorts with equal behavioral dysfunction. Conversely, sham-occluded animals were excluded if they demonstrated <40% or >60% of turns toward the exposed carotid artery. A total of 30 MCAO rats were selected for CTX0E03 cell implantation and 11 MCAO and 10 sham-occluded rats were injected with cell vehicle (HBSS-NAC). Postocclusion behavioral testing resumed at 4 weeks after implantation and was performed weekly for another 8 weeks before the animals were sacrificed.
Bilateral Asymmetry Test
The bilateral asymmetry test (BAT) is a measure of sensorimotor deficits resulting from cortical involvement in stroke damage. 3, 8, 9 The animal was placed in an observation cage after strips of tape (1 × 5 cm) were wound around each of the forepaws in turn. The time from being placed in the cage to the time of contact with the tape and the removal of the tape were recorded. 3, 8, 9 To ensure that performances were not affected by the overall activity of the animals, the difference in time between contact with the tape and removal of the tape was also calculated (affected limb-nonaffected limb).
Whiskers Test
The whiskers test monitors striatal dysfunction by measuring the loss of reflexive lifting of the ipsilateral paw following whiskers strokes contralateral to the damaged hemisphere. 10 For testing, animals were held with 1 forelimb free and moved toward a table top. In animals with normal function, when the whiskers brush the table, the ipsilateral paw reaches out. The number of appropriate limb movements was recorded.
Corners Test
This test assessed striatal dysfunction shortly after a lesion. 10 Rats were placed in a right-angle corner of a caging box with the forelimbs raised off the floor. The direction that the rat turned to move out of the corner was recorded.
Rotameter Test
Biased rotation provides a reliable measure of motor asymmetry (striatal damage) after MCAO, which persists indefinitely. The rotameter system is used to detect both spontaneous rotation bias after saline administration and rotation induced by administration of d-amphetamine sulfate (Sigma). 10 When amphetamine (2.5 mg/kg) is used, rotation activity is increased similarly in control and in stroke animals, but with a marked bias toward the side of stroke damage. Rats were tested 30 minutes after subcutaneous administration of either saline or 2.5 mg/kg amphetamine sulfate with rotations recorded for a further 30 minutes. 8
Functional Observation Battery
The functional observation battery (FOB) consists of noninvasive procedures designed to detect gross functional deficits in animals. 11 Rats were observed in a caging box and 26 parameters (eg, appearance, respiration, gait, clonic and tonic movement, vocalization, body weight) were recorded over a 3-minute session. FOB was conducted 1 week before MCAO, twice between MCAO and cell implantation, and then every 2 weeks after CTX0E03 implantation (see Table 1 for full listing).
CTX0E03 Cell Implantation Surgery
Four weeks after MCAO/sham surgery, MCAO animals were prepared for surgery, anesthetized with halothane in oxygen/nitrous oxide (40:60), and placed into a stereotaxic frame (Kopf). Then, 1 of the 3 doses of CTX0E03 cells (4500, 45 000, or 450 000 cells in a total volume of 9 μL HBSS-NAC), or HBSS-NAC (vehicle) alone in controls, was implanted into 2 sites within the right putamen (coordinates: anterior -1.3 mm, lateral -3.5 mm, ventral -6.5 mm, and anterior -1.8 mm, lateral -4.0 mm, ventral -6.0 mm; anterior and lateral measurements were relative to bregma and ventral relative to dura). All animals were given rehydration therapy of 2 mL Duphalyte in 3 mL glucose saline (IVEX) on the first 2 days of recovery. All rats in the study were recoded after implantation to allow for blinded behavioral testing.
Immunosuppressant therapy
All animals received 20 mg/kg methylprednisolone (Solu-Medrone; Pharmacia, Milton Keynes, UK) subcutaneously, with 1 dose 24 hours prior to either cell or vehicle implantation, 1 dose at implantation and daily for 2 weeks, and 10 mg/kg cyclosporine-A (CsA; Sandoz Pharmaceuticals, East Hanover, NJ) in Cremophor EL (Sigma) carrier subcutaneously with 1 dose 24 hours prior to cell implantation, 1 dose at implantation, and then 6 doses over 2 weeks.
Statistical Analyses for Behavioral Test Measurements
All initial statistical analyses were performed blinded to the treatment status of the groups of animals. Subsequent post hoc analyses were performed after treatments had been unblinded. The initial statistical analysis compared average performances between treatment groups using analyses of variance. Secondary post hoc statistical analyses were performed to evaluate the effectiveness of the treatment (Cohen's d test). As behavioral outcomes demonstrated increased improvement over the course of the postimplantation testing, the percentages of animals that demonstrated recovery of function within treatment groups were compared using Fisher's exact test and chi-square test for trend.
To generate averages of the postimplantation performances for each animal, the data were plotted using linear regression analysis. The value of the fitted regression line at 8 weeks postimplantation (the midpoint of testing) was used as an estimate of the average performance for each animal. For each dependent variable, 1-way analysis of variance was then performed to test for differences between groups (Stata-7SE software, London, UK). For comparisons involving the sham occlusion group, all groups were included and the P value for the overall F test calculated. Comparisons were made without sham group data, allowing baseline data to be assessed as a possible covariate; however, this did not result in an improvement in precision of any of the endpoints and no results are presented with baseline adjustments. Once histological processing was complete, behavioral and cell survival data were compared using Pearson's correlation analysis (Prism software; GraphPad, San Diego, California) to determine possible relationships between surviving cell numbers and behavioral recovery.
Cohen's d test 12 was used post hoc to determine a scale of magnitudes for differences or changes in means. This test was used to objectively determine if a statistically significant difference is of biological importance. Cohen's d measured the effect of standardized differences in the calculated slopes of performance between the high-dose cells treated and vehicle-treated groups. Effect sizes were considered to be small (d < 0.5), medium (d = 0.5 to 0.8), or large (d > 0.8).
Further comparisons were made between treatment groups by analyzing the slopes of the postimplantation performances of animals within groups. The individual slopes that were significantly different from zero were used as an objective index of animals demonstrating recovery from dysfunction over the course of the study. Fisher's exact test 13 (Prism software) was used to examine whether stem cell implantation affected recovery of individual animals in the high-dose implanted group compared with the vehicle-implanted group (P < .05 was indicative of relationship). Chi-square test for trend analysis 13 (Prism software) tested for significant linear relationship (P < .05) between improvements in animal performance and increasing cell dosage in the occluded groups.
Histological Evaluation
Three months after implantations with CTX0E03 cells, animals were sacrificed and brains were removed and cryoprotected in 30% sucrose in phosphate-buffered saline prior to sectioning and histological processing. 3 Brain sectioning, volume analysis, and preliminary histological procedures were all performed blinded. Brains were sectioned in the transverse plane to obtain 50-μm sections through the infarct areas and the implant sites. Starting at the rostral pole, 50-μm sections were collected serially into multi-well culture plates.
Determination of Lesion Volumes
Sections at 1-mm intervals were mounted on glass slides. Lesion volumes, measured as tissue loss in the ipsilateral hemisphere compared to the contralateral hemisphere, were determined using images of unstained sections from all brains using volumetric methods as published. 8 Images were processed (Image ProPlus software; Media Cybernetic, Silver Spring, Maryland) and lesion volumes computed using Simpson's rule. 3 Survival of implanted cells was assessed using indirect immunofluorescence methods, as previously published. 3
Immunohistochemistry-Cell Survival, Migration, Proliferation, and Differentiation of CTX0E03 Cells in the Brain
Survival, proliferation, and differentiation of implanted cells were assessed using indirect immunofluorescence methods. Briefly, sections were washed in phosphate-buffered saline (PBS), incubated overnight at room temperature in a mixture of primary antibodies, washed in PBS, and incubated for 2 hours at room temperature in a mixture of secondary antibodies (Alexa Fluor 488 goat anti-mouse IgG [green], 1:400, Invitrogen and Alexa Fluor 568 goat anti-rabbit IgG [red], 1:2500, Invitrogen). Antibodies directed against human nuclear antigen (HuNuc, MAB1281, 1:500, Chemicon [Millipore, Harrow, UK], and Ki67, RM-9106-S, 1:200, Neomarkers [Thermofisher Scientific, Runcorn, UK]) were used to identify surviving implanted CTX0E03 cells and cell proliferation, respectively. The neuronal marker (MAP2), the oligodendroglial marker (Olig2), and the endothelial markers (CD31, CD62) von Willebrand factor (VWF), and the extracellular matrix marker (MMP2) were used for investigating differentiation of CTX0E03 cells. The use of immunohistochemical techniques for identification of the implanted cells using c-myc as a marker is precluded as antibodies cannot distinguish between the genomic and transgene expressed c-myc. In addition, expression of the cmycER TAM transgene is rapidly silenced following 
Host Brain Responses
Changes in host brain expression of MAP2, Olig2, VWF, and MMP2 were also investigated. In the present study, we analyzed the expression of these markers in serial brain sections from both CTX0E03-treated and respective control groups labeled with antibodies against MAP2 (AB5622, 1:1000, Chemicon), Olig2 (AB9610, 1:500, Chemicon), VWF (A0082, 1:500, Dako, Ely, UK), and MMP2 (AB19167, 1:100, Chemicon). Alexa 488 and Alexa 568 conjugated secondary antibodies were used for visualization by fluorescence microscopy. All sections were counterstained with Hoechst. Host brain expression of Ki67 in the SVZ, as an indicator of host neurogenesis, was also measured in HuNuc/Ki67 stained brain sections (see previous section).
Quantification of MAP2, VWF, and MMP2 expression in rat brain sections. Image capture of the labeled sections and quantification of the fluorescent signals were achieved using Image ProPlus software. Operators were blinded to the study groups. Images of all brain sections (4-6 per brain, per marker) for each marker were captured in a single session so as to minimize variability arising from fluctuations in lighting, exposure, and photobleaching of the samples. Captured images were stored as TIF format files. Using the available image processing tools (eg, thresholding, selection of area of interest, calibration, and measure) in Image Pro Plus software, normalized mean or sum fluorescence values were obtained per hemisphere for each section of brain and transferred using the direct data export (DDE) tool into Excel spreadsheets. Mean fluorescence values per brain and then per group were calculated and exported to a GraphPad Prism statistical software package.
Quantification of Olig2 and Ki67 labeled cells. Cell counting was performed in a blinded manner. Microscopic examination and cell counting of 4 to 6 labeled sections per marker were carried out using a 20x objective on a microscope equipped with epifluorescence optics (Leica DMRB; Milton Keynes, UK). On initial examination of the Olig2 labeled sections, clear regional differences were observed in the striatum, corpus callosum, and the SVZ. Therefore, Olig2 labeled cells were counted and analyzed separately in these 3 brain regions. Ki67 labeled cells were counted in the SVZ of the lateral ventricles. Cell counts were entered into Excel spreadsheets. Mean values were obtained per hemisphere per brain and exported to a GraphPad Prism statistical software package.
Brain Histopathology
Histopathology was conducted on further serial sections from all CTX0E03-dosed groups and control groups. Sections were mounted on SuperFrost (VWR International, Poole, UK) slides and stained with hematoxylin and eosin. All slides were evaluated by an independent certified veterinary pathologist.
Statistical Analyses for Histology Measurements
All results were analyzed for statistical significance using 1-way ANOVA. Comparisons were made between ipsilateral and contralateral hemispheres within and between groups and mean total (combining ipsilateral and contralateral) between groups.
Results
In-Life Observations
Postocclusion
Occluded rats demonstrated gross neurological dysfunction during the occlusion period and the first days of recovery (eg, spontaneous circling, body twisting). This dysfunction was resolved within 7 to 10 days after occlusion and not used to determine any further behavioral improvements. Sham operated rats did not demonstrate any dysfunction. Occluded rats had weight loss in the first 7 to 10 days of recovery and were treated with rehydration therapy until recovery of preocclusion body weight. 11 All animals had enriched diets during the postoperative period. On recovery to preocclusion body weight, behavioral testing demonstrated dysfunction in the tape removal, whiskers reflex, and the rotameter tests.
Effect of Dose of Cell Implantation on Behavioral Recovery Bilateral Asymmetry Test
Tape contact. BAT results demonstrated sensorimotor functional recovery, as shown by the decreased time to contact the affected forelimb in the medium-dose (P = .0002) and highdose implanted animals (P < .0001) when compared to the vehicle-treated MCAO animals from 4 to 12 weeks after implantation. The performances in the medium-dose and highdose treated animals were similar to sham-occluded animals. The treatment effect in the high-dose treated animals was large (Cohen's d = 2.3) with a significant probability of recovery of P = .127. Chi-square test for trend analysis demonstrated a statistically significant trend of recovery with increasing dose (χ 2 = 14.55, df = 1, P = .037).
When the average difference in contact times between the affected and unaffected forelimbs was calculated for postimplantation testing, there were statistically significant improvements in recovery in the medium-dose and high-dose treated groups compared to the vehicle-treated group (P < .001, both groups; Figure 1A and 1B ). There were no statistically significant differences between the control sham lesion group and either the medium-dose or high-dose groups. The treatment effect was large for the high-dose group (Cohen's d = 2.1) with a probability of recovery of P = .0005. Chi-square test for trend analysis was statistically significant (χ 2 = 14.55, df = 1, P = .0001) for a dose-dependent effect of cells on reducing differences in tape contact time.
Tape removal. The first postimplantation performance measurements in the removal of tape from the affected forelimb (4 weeks after implantation) did not show any differences between 3 implanted groups ( Figure 1B and 1D) . Improvements in the performance of the high-dose treated cell groups only became apparent at 6 to 8 weeks after the implantation. The high-dose group had significantly improved recovery (P < .001) in the tape removal test compared to the vehicleimplanted occluded rats. Post hoc analysis of the removal time again demonstrated a large treatment affect (Cohen's d = 2.07) and increased probability of recovery (P = .0022). The chisquare test for trend analysis was statistically significant (χ 2 = 13.70, df = 1, P = .0002) for a dose-dependent effect of cells on improving tape removal time.
When the average difference in removal times between the affected and unaffected forelimbs was calculated for postimplantation testing, improvement in recovery was apparent in the high-dose treated group compared to the vehicle-treated group ( Figure 1B and 1D) (P < .05). The treatment effect was medium (Cohen's d = 0.53) with a probability of recovery of P = .026. The chi-square test for trend analysis was statistically significant (χ 2 = 8.445, df = 1, P = .0037) for a dose-dependent effect of cells on reducing the difference in tape removal times.
Rotameter Test
After amphetamine administration, there was a significant reduction in the mean performance of rotational bias at 6, 8, 10, and 12 weeks after implantation, toward the damaged hemisphere in the low-dose and high-dose cell-implanted groups compared with the vehicle-implanted occluded group (P < .05 and P < .01, respectively), with no evidence for a dose-dependent response (Figure 2 ). There was also a significant difference in performances after implantation after saline administration between the high-dose and vehicle-treated occluded groups, (P < .01). Post hoc analysis demonstrated a large treatment effect in the high-dose group compared to the vehicle-treated group after amphetamine administration (Cohen's d = 1.54) and a small treatment effect (Cohen's d = 0.33) after saline administration.
Whiskers Reflex
Dysfunction in the whiskers reflex was apparent within minutes of occlusion. The high-dose treated group demonstrated some resolution of this dysfunction by the end of the study (12 weeks postimplantation; Figure 3 ). However, there was no significant difference between the high-dose and vehicle-treated occluded groups (P = .055).
Functional Observation Battery
Several measures in the battery that were dysfunctional after occlusion were resolved before the cell implantation (dysfunctional measures shown in bold in Table 2 ). There was no consistent or persistent dysfunction in any of the treatment groups after cell implantation. Some differences were present between treatment groups on particular testing days. For example, there was slightly decreased movement in the shamoccluded and occluded with vehicle groups compared to the cell-treated groups at day 84 after implantation. There was 
Figure 1 Cortical Dysfunction (Bilateral Asymmetry Test)
also a slight difference in the horizontal bar test in the latter half of the study with the sham-occluded animals having a slow release compared to the occluded groups maintaining a grip on the bar. This difference may have been due to the animals in all of the occlusion treatment groups having reduced body weights compared to the sham-occluded animals before and after cell or vehicle implantation. Thus, differences in the horizontal bar test may be because of the heavier nonoccluded animals being unable to support themselves. In general, the FOB data do not provide evidence for a dose-related increase in abnormal behavior.
Postmortem Histological Analysis
Lesion Volume
All occluded animals had significant lesions with a resultant decrease in brain volume ipsilateral to stroke damage. No lesion effect was seen contralateral to stroke damage. Implantation with increasing doses of CTX0E03 did not significantly alter lesion volume compared to vehicle-dosed occluded animals ( Figure 4 ).
Survival, Migration, and Proliferation of CTX0E03 Cells in the Brain
CTX0E03 cell survival was observed in 37% of all animals that received cell implantation (10/27) and in 22% (2/9), 56% (5/9), and 33% (3/9) of low-dose, medium-dose and high-dose animals, respectively. The majority of the surviving CTX0E03 cells were seen in or close to the injection site. Some migration of the implanted CTX0E03 cells was seen and this was restricted to the lesioned striatum ipsilateral to implantation.
The cell proliferation marker Ki67 was colocalized with small populations of HuNuc positive cells at all 3 doses. The proliferation index values for animals implanted with 4500, 45 000, and 450 000 cells were 19.8 ± 16.4, 8.5 ± 11.8, and 2.6 ± 3.2 (mean ± SD), respectively. Significantly less proliferation was observed in the highest dose of cells implanted when compared to the lowest dose. The level of cell proliferation observed did not result in expansion of the implanted cell population.
Correlations of Behavioral Recovery and CTX0E03 Implant Cell Survival
To determine if CTX0E03 cell survival had affected recovery in the whiskers, corners, tape contact/removal, and rotameter tasks, performances were compared to the numbers of surviving cells. Pearson correlations were performed with the numbers of surviving human nuclear positive cells against the performances of the respective host animals. There were no statistically significant correlations between surviving CTX0E03 cell numbers and performances. When performances of all of the grafted animals with surviving cells were 
Left Whiskers
Week Percent Failed Reflexes Note: Only the 450 000-cell dosed subjects demonstrated nonsignificant recovery at the end of the study. Data shown as mean ± SD. compared against all of the grafted animals without surviving cells using t tests, there were again no statistically significant differences between the groups.
Figure 3 Striatal Dysfunction (Whiskers Test)
Differentiation of Surviving Implanted CTX0E03 Cells
Surviving CTX0E03 cells did not express the mature neuronal marker MAP2, although there was upregulation in host tissue around the injection sites ( Figure 5 ). Approximately 8% of the surviving CTX0E03 cells expressed the oligodendroglial marker, Olig2 ( Figure 6 ). The vascular specific markers, CD31, CD62, and Flt4, were expressed in a small proportion of the surviving CTX0E03 cells, comprising approximately 6% collectively. Examples of coexpression of CD31 and CD62 in CTX0E03 cells are shown in Figures 7 and 8 , respectively. Although there was upregulation of the markers VWF and MMP2 around the injection sites, surviving CTX0E03 cells did not express either of these markers. An example of expression of MMP2 around the injection site is shown in Figure 9 .
Host Brain Responses
MAP2. There was no statistically significant effect of MCAO or CTX0E03 cell implantation on MAP2 expression in host brain at 3 months postimplantation.
Olig2. There were clear regional differences in the presence of Olig2 positive cells. Therefore analysis of the sections was performed by counting Olig2 positive cells in the corpus callosum, the striatum, and SVZ of each hemisphere. There were no statistically significant differences in mean counts of Olig2 positive cells in either the corpus callosum or the SVZ of CTX0E03 implanted and control MCAO and sham-lesioned animals.
However, the number of Olig2 immunoreactive cells in the striatum was significantly reduced in CTX0E03 implanted Note: There were no significant differences in the lesion volume between the occluded groups. Data shown as mean ± SD.
Figure 4 Lesion Volumes of All Treatment Groups
animals compared to MCAO controls and sham-lesioned controls (P < .05, Figure 10 ).
Von Willebrand factor. Neither MCAO nor intracerebral implantation of CTX0E03 cells significantly altered VWF expression in the SVZ. However, at the implant site, there was a significant increase in VWF expression in the highest dose group (P = .018) when compared to the MCAO vehicle group (Figure 11 ).
Matrix marker. MCAO alone significantly increased MMP2 expression in host brain when compared to the sham-lesioned group. This increase was unaffected by intracerebral implantation of CTX0E03 cells.
Host cell proliferation in the SVZ. Cell proliferation in the SVZ was investigated using a rabbit monoclonal antibody that recognized both rat and human Ki67 in fluorescence IHC methods. Ki67 labeled cells were located predominantly in the lateral ventricles and therefore analysis was restricted to this region. The Ki67 positive cells in the sections taken at the level of the striatum were counted in the ipsilateral and contralateral SVZ of the lateral ventricles and an average obtained for each brain. The data are summarized in Figure 12 . There was a marked and statistically significant depression in cell proliferation following MCAO compared to the sham-occluded group in both hemispheres. This decrease was greater in the ipsilateral hemisphere. CTX0E03 implants at all 3 doses partially augment this depression to that observed in sham-operated controls, with no statistically significant difference between the sham-occluded and the MCAO-CTX0E03 implanted groups but significant differences between the vehicle-injected and the cell-implanted groups. There is no statistically significant dose-dependent effect on cell proliferation in the SVZ.
Figure 5 Cell Implant and MAP2 Staining
Note: Projected z-stack confocal images of rat brain sections showing the expression of the mature neuronal marker, MAP2 (red), and HuNuc labeled implanted CTX0E03 (green) cells in the ipsilateral hemisphere. Implanted CTX0E03 cells did not differentiate into a mature neuronal MAP2 expressing phenotype (A). However, marked upregulation of MAP2 was observed close to the injection site in the host brain (A) and in some patches in the ischemic host tissue (B).
Figure 6 Cell Implant and Olig2 Staining
Note: Projected z-stack (A, B) and x-section (C) of confocal images of rat brain sections showing the expression of the neural marker Olig2 (red) and the HuNuc labeled implanted CTX0E03 cells (green) in the ipsilateral striatum. Approximately 8% of the implanted CTX0E03 cells also coexpressed this oligodendroglial marker, Olig2, (yellow cells in the z-series projection image B and in the x-sections of the image series shown in C).
Figure 8 Cell Implant and CD62 Staining
Note: Projected z-stack confocal images of rat brain sections showing the expression of the endothelial marker CD62 (red) within the injection bolus of the HuNuc labeled (green) CTX0E03 cells (A) in the ipsilateral hemisphere. Confocal images in panels B and C show that a small population of the implanted CTX0E03 cells differentiate into a CD62 expressing endothelial phenotype.
Figure 7 Cell Implant and CD31 Staining
Note: Projected z-stack confocal images of rat brain sections showing the expression of the endothelial marker CD31 (red) within the injection bolus of the HuNuc labeled (green) CTX0E03 cells (A) in the ipsilateral hemisphere. Confocal images in panels B and C show that differentiation of implanted CTX0E03 cells into a CD31 expressing endothelial phenotype is rare. Pockets of the implanted CTX0E03 were organized into rosettes (white box in A).
Brain Histopathology
Histopathological examination was performed on hematoxylin and eosin stained sections of the brain (including cerebellum and brain stem). In the brain, unilateral damage to the lateral cortex and basal ganglia was detected to a similar degree in MCAO animals with or without CTX0E03 implantation. Localized cellular infiltration (spindle and round cell) was seen around the injection tract to an equal extent in all groups. No other abnormalities were detected in the brain sections examined.
Discussion
The results of behavioral recovery in MCAO-treated rats, presented in this report, confirm and extend our previous findings. 3 CTX0E03, a clonal multipotential human neural stem cell line, shows potential for clinical application in chronic stroke disability. 3 Our previous study demonstrated a significant improvement in behavioral performance following delayed bilateral cell implantation into a rat model of stroke. The present study was designed to anticipate planned clinical trials in 3 main aspects. First, the implanted CTX0E03 cells were derived from manufactured cell banks and are equivalent to those that would be used in future clinical studies. Second, the site of administration (putamen in the damaged hemisphere) is the same as that proposed for clinical trials. Third, the delay in administration of the cells (4 weeks after MCAO) anticipates the planned clinical scenario, where disability following stroke will be determined to be stable prior to treatment.
Figure 9 Cell Implant and MMP2 Staining
Note: Projected z-stack and x-section confocal images rat brain sections showing expression of the metalloproteinase enzyme, MMP2 (red), and HuNuc labeled CTX0E03 cells (green) in the ipsilateral hemisphere. MMP2 was abundantly and exclusively localized to the cell injection site (A). A similar pattern and intensity of MMP2 expression was seen in brains of animals injected with the vehicle. In the cell injected groups, CTX0E03 cell nuclei were tightly woven within the dense MMP2 network (B), surviving CTX0E03 cells (green) did not express the enzyme as shown by the x-section of the image series (C).
Dose-Dependent Effect of CTX0E03 Cells
A common consequence of cortical and striatal damage is contralateral sensory neglect that spontaneously resolves. This neglect, however, is often followed by extended tactile extinction, in which sensory stimulation applied ipsilaterally masks detection of simultaneously applied contralateral stimulation. 10 The medium and high cell-dosed animals demonstrated a reduction of this sensory asymmetry, as evidenced by the reduced time to contact the tape on the affected limb when compared to the occluded animals implanted with the cell vehicle. There is a possibility that the cell implantation may have promoted cortical plasticity in the sensory cortex regions. Similar plasticity of sensory stimuli has been seen in primate models of motor sensory cortical ischemia. 14 The improvement in removing the tape from the affected forelimb, which is independent from the improvement from sensory loss, 11 has not been demonstrated by other groups following implantation or administration of cell therapies. 4 Again, there was evidence of a dose response with the performances being resolved by the high-dose group and relative improvements with the increasing cell concentrations.
The delay in the recovery of function in this behavioral test, first being evident at 6 weeks after implantation, has been observed in previous studies. 8 Implantation of a murine stem cell line (MHP36) into occluded animals demonstrated a delayed improvement in the recovery of this behavior. It was suggested in previous studies that the implanted murine cells were migrating and differentiating into appropriate neurons and the resulting recovery was dependent on the processes of repopulation of neurons in damaged areas of the brain. The current study did not observe cell survival in the majority of the high-dose treated animals. Correlations of behavioral performance with surviving cell numbers did not produce significant statistical results, reinforcing the concept that the implanted stem cells do not replace damaged tissue.
Striatal damage results in the circling of animals shortly after stroke onset with abnormal behavior observed within minutes of recovery from anesthesia in the filament insertion. The use of the rotameter system has been consistent in providing an objective measure of dysfunction with little or no effect on performances because of animal motivation. 9 The highdose and low-dose implantations of CTX0E03 stem cells resulted in significant improvements in the turning bias compared to vehicle-treated animals. Again, there was no correlation between cell survival and performance in this test.
The disruption of forelimb placement after whiskers stimulation started shortly after occlusion. 10 This test is quite useful in that outcome is not dependent on overall activity (allows testing the day after stroke onset), does not require training before occlusion, and results are not dependent on food deprivation or reward. The reflex has, in our studies, been a robust binary response with a complete loss in affected animals. Previous method development studies have found that a MCAO lesion volume of around 50 mm 3 is required before dysfunction is evident in this test. There was a suggestion of a slight improvement in recovery in the high-dose group toward the end of this study, which may have progressed further in a study of longer duration.
The continued improvement in behavioral performance in the high-dose group suggests that recovery is a dynamic process where the brain continues to change. These results suggest that the cells produce a bystander effect, namely that the implanted stem cells release some elements into the brain that either promote host neuronal plasticity or vascular growth into the damaged areas that then results in improved behavioral recovery. 15, 16 Our observation, that surviving implanted cells do not possess a mature neuronal phenotype, is in line with published reports of differentiation of neural stem cells into vascular cell types 17 and angiogenic mechanisms 18, 19 that appear to aid recovery in animal models of stroke.
Secondary Statistical Analyses
The post hoc statistical analyses (Cohen's d, Fisher's exact, and chi-square test for trend analysis) were used to determine the impact of the cell implantation on behavioral recovery. The initial performances at 4 weeks after implantation were similar to those seen after MCAO. Starting at 6 to 8 weeks after implantation, the performances in the medium-and high-dose treated groups demonstrated improvements. This delay in recovery has been seen previously with the implantation of murine neural stem cells into rats after MCAO. The Cohen's d test was used to determine the scale of improvements. Anticipating a clinical application with stereotaxic placement of cells into patients, we attempted to determine if the differences in behavioral outcome would merit a surgical procedure. The use of nonzero slopes as a marker of improvement was determined to be an objective, rigorous measure. This measure allowed us to determine the numbers of animals that had recovery of function within treatment groups, giving us a marker of success that could then be used to determine if the increased cell dose resulted in a greater percentage of animals within a group having recovery of function over the course of the study.
Immunosuppressant Therapy
The administration of a dual immunosuppressant therapy for 2 weeks after cell implantation was determined from earlier pilot studies. Solumedrone was administered to reduce inflammation in the brain following the insertion of the injection needle into the brain and also to act as an analgesic. The 2-week administration of cyclosporine A (CsA) was chosen following a previous pilot study comparing cell survival at 12 weeks after implantation with administration of no CsA, 2, 6, or 12 weeks of CsA (data not shown). There was no advantage provided in continued administration of CsA surgery in cell survival. Disruption of the blood brain barrier should be repaired within 2 weeks of the implantation surgery, restoring the immunoprivileged status of the brain. A reduced period of CsA administration also provides benefits in animal welfare with reduced numbers of injections and better gain of body weight over the study period.
Functional Observational Battery
The FOB 11 used in this study found behavioral dysfunction because of stroke onset, which ranged from mild (ungroomed fur) to severe (seizure activity) measures and was resolved before cell implantation. Increasing concentrations of implants raised some concerns that the introduction of a large volume of cells may have a deleterious effect on overall behavior. The wide range of measures used in the FOB provided further evidence that introducing cells into the damaged brain did not exacerbate any behavioral dysfunction.
Host Tissue Responses
In the adult rodent brain, the SVZ contains proliferating progenitor cells and relatively quiescent neural stem cells. 20 These stem cells are known to give rise to neurons and glia throughout adult life. 21, 22 Here, we report that weeks and months after MCAO, there is a significant decrease in the number of Ki67 positive cells in the SVZ, indicating a reduction in cell division and a likely reduction in neuro and gliagenesis. Intracerebral implantation of CTX0E03 into MCAO-lesioned brains significantly restores host proliferation in the neurogenic SVZ. The data presented here are in concordance with that reported by other researchers, namely a marked impairment of cell proliferation after brain injury. Ekdahl et al 23 attributed this impairment to inflammation; however, increased proliferation in the SVZ has also been noted at relatively short periods following injury in the adult brain. [24] [25] [26] We conclude that in the present study, at 3 months poststroke, an inflammatory mechanism may operate to suppress cell proliferation and that an antiinflammatory influence may be exerted by CTX0E03 at an early stage postimplantation to counteract the effects of MCAO.
The phenotype of these newly born cells remains to be elucidated. It is highly likely that these cells in the SVZ differentiate into neurons, astrocytes, and oligodendrocytes, as has been demonstrated by the work of Garcia-Verdugo et al. 21 It is also possible that Ki67 is staining dividing inflammatory cells that may then contribute to graft rejection. However, this is unlikely because of the location of the dividing cells that are reported here (in the SVZ and not in the region of the transplant. Also, vehicle and cell implanted groups gave rise to a similar magnitude of inflammatory response in the MCAO animals. Furthermore, inflammatory cells associated with rejection are largely hematopoietic, arising from either infiltration of macrophages from vasculature or resident microglia within the implant region. 27 Although the exact mode of action of CTX0E03 cells remains elusive, the significant increase in cell proliferation in the brains of animals implanted with CTX0E03 may contribute partly to postocclusion repair and protection of the penumbra, and may lead to enhanced compensatory networks arising elsewhere. The angiogenic effect of CTX0E03 at the site of implantation may indicate an attempt at reconstruction of vasculature and restoration of blood supply to the infarct territory. Indeed, angiogenesis and neurogenesis, as observed in this study, may be coupled processes similar to that observed in a coculture system employing neural progenitors and activated endothelial cells. 28 The significance of the CTX0E03-induced decrease in Olig2 expression in the striatum remains to be investigated further. It is possible that here, as in studies reported by other researchers, 29 silencing of Olig2 is commensurate with Pax6 expression, which is known to be a marker of cells fated to produce neurons. Thus, intracerebral implantation of CTX0E03 may drive precursor cells toward a neuronal rather than oligodendroglial fate.
Although proliferation of grafted CTX0E03 cells was observed, there were no overt CTX0E03-associated phenotypic, morphological changes (MAP2 and MMP2), or adverse pathology in the host brain.
Conclusions
This study found that implantation of CTX0E03 cells into the putamen ipsilateral to occlusion promoted a significant behavioral recovery in rats. The bilateral asymmetry test results, evaluating sensorimotor dysfunction, showed an early dose-dependent sensory component (time to contact tape) and a latent high-dose motor component (time to remove tape). When motor asymmetry, because of striatal damage, was measured by the rotameter test, it showed significant improvement in the low-and high-dose groups. Histological analysis found surviving CTX0E03 cells in less than half of the brains of implanted animals (22%, 56%, and 33% of low-, medium-and high-dose groups, respectively). Implanted CTX0E03 cells did not differentiate into mature neurons. Surviving cell growth was restricted to the ipsilateral striatal regions in the brain and the levels of cell proliferation observed did not result in an expansion of the implanted cell population.
CTX0E03 cells possess biological attributes that are entirely desirable for clinical applications for stroke therapy, including stable expandability in vitro, survival-independent mode of action in vivo, limited migration potential, and low risk in the long term with absence of cell treatment-induced histopathology.
